Insmed Incorporated (NASDAQ:INSM – Get Rating) shot up 15.1% on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $25.04 and last traded at $25.04. 8,920 shares were traded during trading, a decline of 99% from the average session volume of 1,028,419 shares. The stock had previously closed at $21.76.
The biopharmaceutical company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.09. Insmed had a negative return on equity of 120.54% and a negative net margin of 188.04%. The company had revenue of $65.20 million for the quarter, compared to analysts’ expectations of $58.92 million. During the same period last year, the firm earned ($0.94) EPS. Insmed’s revenue for the quarter was up 43.6% compared to the same quarter last year.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on INSM shares. The Goldman Sachs Group decreased their target price on Insmed from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, May 24th. Morgan Stanley decreased their target price on Insmed from $46.00 to $41.00 and set an “overweight” rating on the stock in a report on Friday, July 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.67.
Insiders Place Their Bets
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Ensign Peak Advisors Inc purchased a new position in shares of Insmed during the fourth quarter valued at about $767,000. Calton & Associates Inc. grew its position in shares of Insmed by 15.7% during the first quarter. Calton & Associates Inc. now owns 9,801 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 1,331 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Insmed by 254.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 409,216 shares of the biopharmaceutical company’s stock valued at $11,147,000 after purchasing an additional 293,890 shares in the last quarter. WCM Investment Management LLC grew its position in shares of Insmed by 3.9% during the first quarter. WCM Investment Management LLC now owns 251,642 shares of the biopharmaceutical company’s stock valued at $5,914,000 after purchasing an additional 9,467 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Insmed during the fourth quarter valued at about $242,000.
Insmed Stock Up 10.7 %
The stock has a 50-day moving average price of $21.03 and a two-hundred day moving average price of $21.98. The company has a current ratio of 6.04, a quick ratio of 5.52 and a debt-to-equity ratio of 6.73.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.